4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no…
Sweet Security Research Identifies Go Implementation of Node2Shell Vulnerability, Expanding Attack Surface to Major HTTP Frameworks
Savills Hong Kong Hosts Grand Reception to Celebrate 40th Anniversary
Micro-Dramas After 1 September 2026 – How China (Mainland) Rewrote the Rules
Hong Kong, Singapore, Tokyo: A Data Centre Comparison for Asian Site Selection